Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications.
Benign prostatic hyperplasia (BPH) is highly prevalent in men older than 50 years and is associated with a range of lower urinary tract symptoms that may have a negative impact on patient quality of life. Alpha(1)-adrenergic receptor antagonists are the first-line of pharmacologic management for lower urinary tract symptoms associated with BPH. However, many patients take multiple medications that may exacerbate age-related orthostatic hypotension. Thus, clinicians should evaluate the treatment of these patients within the context of comorbidities. The present article discusses the role of non-subtype-selective and subtype-selective alpha(1)-adrenergic receptor antagonists in the clinical management of BPH. Safety and tolerability for both non-subtype-selective and subtype-selective alpha(1)-adrenergic receptor antagonists for patients with BPH are also reviewed.
Fine
Shari R
SR
Christ Hospital, Jersey City, NJ, USA. sfine324@verizon.net
Ginsberg
Phillip
P
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D000367:Age Factors; D000368:Aged; D000375:Aging / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007022:Hypotension / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014555:Urination Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology
D000317:Adrenergic alpha-Antagonists